Objective
to compare the efficacy and safety of the use of ticagrelor or prasugrel in patients with acute coronary syndromes planned for PCI
Study
multicentre open label randomised trial
Population
patients with STEMI (41%) or UA (13%) or NSTEMI (46%) undergoing PCI (84%)
Endpoints
composite of death, MI or stroke at 1 year
Conclusion
the incidence at 1 year of death, MI or stroke was significantly lower with prasugrel compared to ticagrelor for treatment of patients with ACS with planned PCI while the incidence of bleeding was not different
Schüpke et al. N Engl J Med. 2019;381:1524-34
